Australia’s Monash Cancer Centre is First to Treat Breast Cancer Patient with iCAD’s Xoft System

Australia’s Monash Cancer Centre is First to Treat Breast Cancer Patient with iCAD’s Xoft System
A woman with early-stage breast cancer became the first patient to receive a single, concentrated dose of intraoperative radiation therapy (IORT) following surgery using the Xoft system, in a clinical study taking place in the United States and elsewhere. Made by iCAD of Nashua, New Hampshire, the Xoft Axxent Electronic Brachytherapy System has already won approval from U.S. and European authorities to treat breast cancer and other solid cancers. The patient was treated at the Monash Cancer Centre in Melbourne, Australia, iCAD said in a press release, noting that the procedure can be completed in one eight-minute session, compared to six to eight weeks for standard radiation therapy, The clinical study, called the ExBRT trial (NCT01644669), is testing the safety and efficacy of single-dose and isotope-free radiation using the Xoft System against traditional whole breast irradiation in women with early-stage cancer. It plans to enroll about 1,200 people at 26 sites across the United States as well as one site each in Australia and Portugal. Many centers are still recruiting patients; more information is available here. Using the Xoft System, oncologists and surgeons work together during a lumpectomy to administer a concentrated but low-energy dose of radiation, given through a small balloon applicator inserted into the breast cavity created by the surgery. This potentially directs radiation to the cancer site while preserving nearby healthy tissue. It uses X-ray radiation instead of radioactive material as a treatment, allowing medical personnel to remain in the room with the patient. "Intraoperative radiotherapy will offer women with early-stage breast cancer another therapeutic option, and, we believe, a better patient experience with
Subscribe or to access all post and page content.